Combination therapy enhances CD8+ T cell-mediated killing in ovarian cancer, suggesting improved treatment options.
The work presented here demonstrates the efficacy of PAK inhibition and PD-1 checkpoint blockade as a combination therapy for high-grade serous ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: